A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly less pain immediately after injection than SC ...

BASEL, Switzerland, October 29 /PRNewswire/ -- A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly ...

being a common adverse event and a burden for patients with chronic kidney disease (CKD).

Japanese drug major Chugai Pharmaceutical says it has obtained approval from the Ministry of Health, Labor and Welfare for Mircera (epoetin beta pegol) injection syringe 12.5μg, the lowest content ...

(4) For patients not currently treated with an erythropoiesis stimulating agent (ESA), the recommended starting dose is 0.6 microgram/kg body weight, administered once every two weeks as a single ...

Researchers have successfully developed a new electrophoretic method for detecting MIRCERA and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically enhanced ...